Lam Research (LRCX) Shares Drop 9% After Disappointing Q4 Foreca
Lam Research (LRCX) shares fell 9% after its Q4 revenue forecast missed expectations due to supply chain issues. Analysts cut price targets, with Needham reducing its target to $290 and Morgan Stanley to $339. Wells Fargo remains optimistic about long-term growth. The stock is trading 45.6% above its GF Value™ of $160.71, indicating overvaluation, despite a strong GF Score™ of 93.
How this was made
The 30-second read
Why it matters
The guidance miss triggers immediate downside risk for LRCX and may pressure peers in the semiconductor equipment space.
Market read
The article provides fresh guidance data for a large‑cap tech stock, causing a notable price move and prompting analyst target cuts, making it highly relevant for short‑term traders.
What to watch
Insider selling and an elevated P/E multiple suggest valuation concerns beyond the immediate guidance miss.
Background
Lam Research, a leading supplier of wafer‑fabrication equipment, issued a December‑quarter revenue forecast that fell short of market expectations, prompting a 9% share decline and analyst target reductions.
Ticker impact
Lam Research shares fell 9% after issuing a December‑quarter revenue forecast that missed investor expectations.
downward pressure as the market prices in weaker revenue guidance
Guidance miss for a large‑cap semiconductor equipment maker triggered a 9% intraday drop and analyst target cuts.
Market effects
Semiconductor equipment sector may face broader pressure from supply‑chain constraints and weaker guidance.
U.S. technology stocks could see a modest pullback as investors digest the downgrade.
Global chip‑maker valuations may be affected as the guidance signals slower demand growth.
Counterpoint
Long‑term investors might view the dip as a buying opportunity given Lam's strong fundamentals and market position.
Key entities
- companyLam Research Corp
Semiconductor equipment manufacturer reporting weaker guidance.
- analystNeedham
Reduced price target from $390 to $290 after the guidance miss.
- analystMorgan Stanley
Lowered price target to $339 following the guidance shortfall.
